Drug intelligence / Profile preview

TQB2709

Development stage: Unknown
Lead developer: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TQB2709 is a biosimilar of daratumumab, developed as an intravenous injection. It is being evaluated for its pharmacokinetic similarity, safety, tolerability, and immunogenicity compared to the reference product Zhaoke (兆珂®, the Chinese brand name for daratumumab) in healthy male volunteers. Daratumumab is a monoclonal antibody that targets CD38 and is primarily used in the treatment of multiple myeloma. The development of TQB2709 aims to provide an alternative to existing daratumumab products by demonstrating comparable efficacy and safety profiles[1].

Targets

CD38 (Cluster of Differentiation 38)

Beyond the preview

Go deeper on TQB2709.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB2709.

Explore the full profile